CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare ConferenceGlobeNewsWire • 05/06/26
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss EstimatesZacks Investment Research • 05/05/26
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/05/26
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsGlobeNewsWire • 05/04/26
Why the Market Dipped But CRISPR Therapeutics AG (CRSP) Gained TodayZacks Investment Research • 04/28/26
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/28/26
CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards?Zacks Investment Research • 04/27/26
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key FactsZacks Investment Research • 04/22/26
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?The Motley Fool • 04/21/26
CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptSeeking Alpha • 04/13/26
This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic AreaThe Motley Fool • 04/08/26
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/07/26
Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position?The Motley Fool • 04/07/26
The Personalized Biotech Flywheel Cathie Wood Built Is Still a Winning Bet Today24/7 Wall Street • 04/03/26
I Expect Crispr Therapeutics To Break Out As 2026 Revenue Exceeds ExpectationsSeeking Alpha • 03/31/26
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market TodayZacks Investment Research • 03/25/26
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 03/19/26
From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here24/7 Wall Street • 03/17/26